New hope for heart patients: drugs target hidden inflammation from blood mutations

NCT ID NCT06097663

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two experimental drugs, DFV890 (a daily pill) and MAS825 (a single shot), in 31 adults with coronary heart disease and a blood condition called CHIP. The goal was to see if these drugs could reduce specific markers of inflammation linked to heart risk. The trial was completed and focused on safety and how well the drugs lowered inflammation levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clonal hematopoiesis of indeterminate potential coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) CORONARY HEART DISEASE

Contacts and locations

Locations

Novartis Investigative Site

Montreal, Quebec, H1T 1C8, Canada
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Bonn, 53105, Germany
Novartis Investigative Site

München, 80636, Germany
Vanderbilt University Medical Cent

Nashville, Tennessee, 37232-8805, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.